Oncotarget: Both BRCA1-wild type and -mutant triple-negative breast cancers show

Oncotarget



Volume 11 Issue 8

features Figure 8, “MLN4924 treatment induces DNA damage by stabilizing CDT1 and accumulates the cells in S phase which are enhanced by MLN4924/cisplatin co-treatment,” by Misra, et al.

Moreover, adding MLN4924 to the standard TNBC chemotherapeutic agent cisplatin increased the DNA damage level, further enhancing the sensitivity.

In vivo

, MLN4924 reduced tumor growth in a

NOD-SCID

mouse xenograft model by inducing DNA damage which was further augmented with the MLN4924 and cisplatin cotreatment.

Taken together, we demonstrated the mechanism of TNBC sensitization by the MLN4924 and MLN4924/cisplatin treatments irrespective of BRCA1 status, provided a strong justification for using MLN4924 alone or in combination with cisplatin, and identified a genetic background in which this combination will be particularly effective.

Dr. Alo Ray

from the Department of Pathology and the Comprehensive Cancer Center at the

Ohio State University

in Columbus Ohio said, ”

Triple-negative breast cancer (TNBC) comprises 15–20% of breast cancer.

”

“Triple-negative breast cancer (TNBC) comprises 15–20% of breast cancer.”

– Dr. Alo Ray, Center for Radiological Research, Department of Pathology and the Comprehensive Cancer Center at the Ohio State University

However, whether MLN4924 sensitizes breast tumors

in vivo

, is cytotoxic to BRCA1-mutated TNBC, and sensitizes TNBC to standard TNBC chemotherapeutics have not been investigated.

Here, we evaluated the efficacy of MLN4924 as a therapeutic agent in BRCA1-wild type and -mutant cells and examined if MLN4924 in combination with cisplatin, a standard platinum-based TNBC chemotherapeutic, enhances cytotoxicity.

Our results demonstrated that TNBC cell lines show a higher sensitivity to MLN4924 compared to cell lines representing other breast cancer subtypes due to the overexpression of NAE1 in TNBC compared to non-TNBC subtypes.

MLN4924 treatment resulted in >4N DNA content due to the re-replication of DNA leading to the accumulation of DNA damage,

apoptosis

, and

senescence

.

In vivo

, MLN4924 significantly inhibited the growth of a TNBC xenograft model by inducing DNA damage, and MLN4924/cisplatin combination further reduced tumor growth by enhancing DNA damage.

The Ray Research Team concluded in their


Oncotarget

Research Paper

that Additionally, the presence of p53 mutation in TNBC cells may promote re-replication upon MLN4924 treatment since activation of

p53

by ATM/ATR/Chk2 regulates the re-replication through the induction of

p21

supporting that p53 status is prognostic of outcome and

MLN4924

treatment response of TNBC. Collectively, our results established the molecular mechanism by which MLN4924 induces TNBC cell death and enhances cisplatin sensitivity, provided the rationale of combining MLN4924 with cisplatin in both BRCA1-wild type and mutant TNBCs, and identified a cancer genetic background where this combination will be more effective.

###

Sign up for free Altmetric alerts about this article

Full text

–

https:/

/

doi.

org/

10.

18632/

oncotarget.

27485

Correspondence to

– Alo Ray –

[email protected]

Keywords

–


triple-negative breast cancer

,

MLN4924

,

cisplatin

,

cell cycle

,

DNA damage

About

Oncotarget

Oncotarget

is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about

Oncotarget

, please visit

http://www.

oncotarget.

com

or connect with:

SoundCloud –


https:/

/

soundcloud.

com/

oncotarget



Facebook –


https:/

/

www.

facebook.

com/

Oncotarget/

Twitter –


https:/

/

twitter.

com/

oncotarget



LinkedIn –


https:/

/

www.

linkedin.

com/

company/

oncotarget



Pinterest –


https:/

/

www.

pinterest.

com/

oncotarget/

Reddit –


https:/

/

www.

reddit.

com/

user/

Oncotarget/

Oncotarget

is published by Impact Journals, LLC please visit

http://www.

ImpactJournals.

com

or connect with

@ImpactJrnls

Media Contact



[email protected]



18009220957×105